AC 102
Alternative Names: AC-102Latest Information Update: 03 Apr 2024
At a glance
- Originator AudioCure Pharma
- Developer AudioCure Pharma; Radboud University Nijmegen Medical Centre
- Class Anti-inflammatories; Carbolines; Small molecules
- Mechanism of Action Antioxidants; Apoptosis inhibitors; Brain-derived neurotrophic factor expression stimulants; Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sensorineural hearing loss
- No development reported Hearing loss
Most Recent Events
- 01 Apr 2024 Pharmacodynamics data from preclinical trial in Hearing loss released by AudioCure Pharma
- 28 Dec 2023 No recent reports of development identified for phase-I development in Hearing loss(In volunteers) in Netherlands (Intratympanic, Suspension)
- 10 Mar 2022 Phase-II clinical trials in Sensorineural hearing loss (In the elderly, In adults) in Germany, Czech Republic, Austria (Intratympanic) (EudraCT2021-004323-33)